Develop and market pharmaceutical products for various therapeutic areas. Offer treatments for Alzheimer's disease/dementia with Lewy bodies. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
If every debt were paid off today, $388.6M would still be left in the vault — a solid cushion for hard times.
The market pays 34.2× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $1.6B in the vault; even if every debt were paid off, $388.6M would remain.
It pays out $1.04 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.